These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 8992917)

  • 1. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death.
    Owens DK; Sanders GD; Harris RA; McDonald KM; Heidenreich PA; Dembitzer AD; Hlatky MA
    Ann Intern Med; 1997 Jan; 126(1):1-12. PubMed ID: 8992917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.
    Owens DK; Sanders GD; Heidenreich PA; McDonald KM; Hlatky MA
    Am Heart J; 2002 Sep; 144(3):440-8. PubMed ID: 12228780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.
    Sanders GD; Hlatky MA; Every NR; McDonald KM; Heidenreich PA; Parsons LS; Owens DK
    Ann Intern Med; 2001 Nov; 135(10):870-83. PubMed ID: 11712877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of implantable cardioverter-defibrillators.
    Sanders GD; Hlatky MA; Owens DK
    N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-benefit analysis of primary prevention of sudden cardiac death with an implantable cardioverter defibrillator versus amiodarone in Canada.
    Deniz HB; Ward A; Jaime Caro J; Alvarez P; Sadri H
    Curr Med Res Opin; 2009 Mar; 25(3):617-26. PubMed ID: 19232036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
    Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone.
    Caro JJ; Ward A; Deniz HB; O'Brien JA; Ehreth JL
    Value Health; 2007; 10(1):13-22. PubMed ID: 17261112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of implantable cardioverter defibrillator therapy versus drug therapy for patients at high risk of sudden cardiac death.
    Spath MA; O'Brien BJ
    Pharmacoeconomics; 2002; 20(11):727-38. PubMed ID: 12201792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of the implantable cardioverter defibrillator: a preliminary analysis.
    O'Brien BJ; Buxton MJ; Rushby JA
    Br Heart J; 1992 Aug; 68(2):241-5. PubMed ID: 1389748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of implantable cardioverter-defibrillators in Brazil: primary prevention analysis in the public sector.
    Ribeiro RA; Stella SF; Camey SA; Zimerman LI; Pimentel M; Rohde LE; Polanczyk CA
    Value Health; 2010; 13(2):160-8. PubMed ID: 19725912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are implantable cardioverter- defibrillators cost-effective?
    Naik AM; Peter CT
    Curr Cardiol Rep; 2000 Jul; 2(4):341-5. PubMed ID: 10953269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy.
    Larsen GC; Manolis AS; Sonnenberg FA; Beshansky JR; Estes NA; Pauker SG
    J Am Coll Cardiol; 1992 May; 19(6):1323-34. PubMed ID: 1564234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone.
    Gali WL; Sarabanda AV; Baggio JM; Ferreira LG; Gomes GG; Marin-Neto JA; Junqueira LF
    Europace; 2014 May; 16(5):674-80. PubMed ID: 24481778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review.
    Parkes J; Bryant J; Milne R
    Health Technol Assess; 2000; 4(26):1-69. PubMed ID: 11086270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are implantable cardioverter-defribrillators always superior to amiodarone?
    Doggrell SA
    Expert Opin Pharmacother; 2003 Nov; 4(11):2111-4. PubMed ID: 14596664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Children with Cardiac Conditions Associated with Risk for Sudden Cardiac Death.
    Haag MB; Hersh AR; Toffey DE; Sargent JA; Stecker EC; Heitner SB; Caughey AB; Balaji S
    Pediatr Cardiol; 2020 Oct; 41(7):1484-1491. PubMed ID: 32623612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost effectiveness of implantable cardioverter defibrillators: a systematic review of economic evaluations.
    Gialama F; Prezerakos P; Maniadakis N
    Appl Health Econ Health Policy; 2014 Feb; 12(1):41-9. PubMed ID: 24243517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
    Chan PS; Stein K; Chow T; Fendrick M; Bigger JT; Vijan S
    J Am Coll Cardiol; 2006 Jul; 48(1):112-21. PubMed ID: 16814657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
    Bokhari F; Newman D; Greene M; Korley V; Mangat I; Dorian P
    Circulation; 2004 Jul; 110(2):112-6. PubMed ID: 15238454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
    Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.